Boehringer Ingelheim Sponsors PCV2 Research Projects

GERMANY - Since 2007, Boehringer Ingelheim Animal Health has funded independent European research projects related to Porcine Circovirus Type 2 (PCV2) infection and associated diseases.
calendar icon 19 March 2013
clock icon 3 minute read

So far, 17 research projects have been awarded, each supported with 25,000 euro, in total 425,000 euro. In the past five years, 50 research projects were submitted to the European PCV2 research award, demonstrating the continuous interest and need for applied PCV2 research.

The award winners with members of the review board and George Heidgerken, Boehringer Ingelheim Animal Health (on the right).

The 2012 European PCV2 research awards were recently presented to the successful investigators by the head of the review board, Professor Maurice Pensaert, former head of the Laboratory of Virology of Ghent University in Belgium, and George Heidgerken, Senior Vice President Boehringer Ingelheim Animal Health.

In the 6th edition the independent review board selected the following projects to be awarded:

  • Effect of maternal derived immunity on PCV2 infection dynamics and production parameters in PCV2 vaccinated pigs (Professor Joaquim Segalés and Dr Marina Sibila, CReSA and Universitat Autònoma, Barcelona, Spain)
  • Are amino acids 169 and 173 of PCV capsid protein determinant for virulence? (Dr Beatrice Grasland, Anses – LERAPP laboratory, Ploufragan, France)
  • Does prophylactic treatment with Iscom-Matrix adjuvant affect a subsequent PCV2 infection in pigs? (Professor Caroline Fossum, Swedish University of Agricultural Sciences, Uppsala, Sweden)

More than 40 European scientists participated in the award ceremony, which - for the first time - took place in Hanover, Germany, where Boehringer Ingelheim recently opened a new international research site. More than 50 employees are already working on researching innovative vaccines for livestock at the Boehringer Ingelheim Veterinary Research Center. The company has invested more than 40 million euro in this state-of-the-art research facility, thus underlining the commitment of Boehringer Ingelheim to research and development in animal health.

Visit our PCVAD/PMWS page by clicking here.

© 2000 - 2024 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.